- Report
- May 2026
- 150 Pages
Global
From €5413EUR$5,950USD£4,623GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- April 2026
- 160 Pages
Global
From €3021EUR$3,320USD£2,580GBP
€3776EUR$4,150USD£3,225GBP
- Report
- August 2025
- 182 Pages
Global
From €3225EUR$3,545USD£2,755GBP
€3584EUR$3,939USD£3,061GBP
- Report
- June 2026
- 200 Pages
Global
From €2720EUR$2,990USD£2,323GBP
- Report
- April 2026
- 200 Pages
Global
From €2720EUR$2,990USD£2,323GBP
- Report
- April 2026
- 200 Pages
Global
From €2720EUR$2,990USD£2,323GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- May 2026
- 200 Pages
Global
From €2537EUR$2,789USD£2,167GBP
- Report
- April 2026
- 148 Pages
Global
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- January 2026
- 130 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- August 2025
- 150 Pages
Global
From €2875EUR$3,160USD£2,455GBP
€3594EUR$3,950USD£3,069GBP
- Report
- August 2025
- 200 Pages
United States
From €2265EUR$2,490USD£1,935GBP

Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes medications.
Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more